AbbVie (ABBV) Goodwill & Intangibles (2012 - 2026)
AbbVie (ABBV) reported Goodwill & Intangibles of $86.4 billion for Q1 2026, down 7.82% year-over-year from $93.8 billion in Q1 2025, and down 2.08% on a QoQ basis from $88.3 billion in Q4 2025.
AbbVie (ABBV) has 15 years of Goodwill & Intangibles data on file, last reported at $86.4 billion in Q1 2026.
- Quarterly Goodwill & Intangibles fell 7.82% year-over-year to $86.4 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $86.4 billion (down 7.82% YoY) and the FY2025 annual result came in at $88.3 billion, down 7.1% from the prior year.
- Goodwill & Intangibles retreated to $86.4 billion in Q1 2026 per ABBV's latest filing, from $88.3 billion in the prior quarter.
- Across five years, Goodwill & Intangibles topped out at $106.3 billion in Q1 2022 and bottomed at $36.3 billion in Q3 2025.
- The 5-year median for Goodwill & Intangibles is $95.0 billion (2024), against an average of $92.0 billion.
- The widest annual swing landed in 2024, when Goodwill & Intangibles advanced 12.4%; it then plunged 64.35% in 2025.
- Tracing ABBV's Goodwill & Intangibles over 5 years: stood at $99.6 billion in 2022, then retreated by 11.74% to $87.9 billion in 2023, then grew by 8.1% to $95.0 billion in 2024, then retreated by 7.1% to $88.3 billion in 2025, then slipped by 2.08% to $86.4 billion in 2026.
- Per Business Quant, the three latest ABBV Goodwill & Intangibles figures stand at $86.4 billion (Q1 2026), $88.3 billion (Q4 2025), and $36.3 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 86.44 Bn |
| Dec 31, 2025 | 88.28 Bn |
| Sep 30, 2025 | 36.34 Bn |
| Jun 30, 2025 | 92.67 Bn |
| Mar 31, 2025 | 93.77 Bn |
| Dec 31, 2024 | 95.02 Bn |
| Sep 30, 2024 | 101.94 Bn |
| Jun 30, 2024 | 93.63 Bn |
| Mar 31, 2024 | 95.65 Bn |
| Dec 31, 2023 | 87.90 Bn |
| Sep 30, 2023 | 90.69 Bn |
| Jun 30, 2023 | 95.09 Bn |
| Mar 31, 2023 | 97.07 Bn |
| Dec 31, 2022 | 99.60 Bn |
| Sep 30, 2022 | 100.45 Bn |
| Jun 30, 2022 | 103.85 Bn |
| Mar 31, 2022 | 106.28 Bn |
| Dec 31, 2021 | 108.33 Bn |
| Sep 30, 2021 | 109.75 Bn |
| Jun 30, 2021 | 111.74 Bn |
| Mar 31, 2021 | 113.64 Bn |
| Dec 31, 2020 | 116.00 Bn |
| Sep 30, 2020 | 117.44 Bn |
| Jun 30, 2020 | 119.13 Bn |
| Mar 31, 2020 | 33.76 Bn |
| Dec 31, 2019 | 34.25 Bn |
| Sep 30, 2019 | 34.57 Bn |
| Jun 30, 2019 | 36.10 Bn |
| Mar 31, 2019 | 36.45 Bn |
| Dec 31, 2018 | 36.90 Bn |
| Sep 30, 2018 | 21.82 Bn |
| Jun 30, 2018 | 42.60 Bn |
| Mar 31, 2018 | 43.11 Bn |
| Dec 31, 2017 | 43.34 Bn |
| Sep 30, 2017 | 43.92 Bn |
| Jun 30, 2017 | 44.02 Bn |
| Mar 31, 2017 | 44.12 Bn |
| Dec 31, 2016 | 44.31 Bn |
| Sep 30, 2016 | 44.77 Bn |
| Jun 30, 2016 | 34.77 Bn |
| Mar 31, 2016 | 32.79 Bn |
| Dec 31, 2015 | 32.88 Bn |
| Sep 30, 2015 | 33.07 Bn |
| Jun 30, 2015 | 25.57 Bn |
| Mar 31, 2015 | 11.64 Bn |
| Dec 31, 2014 | 5.94 Bn |
| Sep 30, 2014 | 12.13 Bn |
| Jun 30, 2014 | 12.44 Bn |
| Mar 31, 2014 | 8.07 Bn |
| Dec 31, 2013 | 7.72 Bn |
| Sep 30, 2013 | 12.46 Bn |
| Jun 30, 2013 | 7.78 Bn |
| Mar 31, 2013 | 12.12 Bn |
| Dec 31, 2012 | 8.03 Bn |